文献速递前列腺增生与排尿功能障碍

侵入性尿动力学检查治疗女性膀胱过度活动症的长期成本效果

Long-term cost-effectiveness of invasive urodynamic studies for overactive bladder in women.
PubMed 文献 · BJU Int · 2025-04-19

基于FUTURE试验建立经济模型,评估女性难治性膀胱过度活动症(OAB)中侵入性尿动力学检查(UDS)联合综合临床评估(CCA)相比单纯CCA的长期成本效果。结论认为从英国视角看UDS不太可能具有成本效果。

要点

  • UDS联合CCA相比单纯CCA终身成本高1380英镑,QALYs少0.002。

核心结论

  • 对于难治性OAB女性,从英国视角和终身 horizon 看,UDS不太可能具有成本效果。

研究设计与样本

  • 基于FUTURE随机对照试验(评估UDS联合CCA与单纯CCA)构建经济模型,模拟24个月结果并外推终身成本与QALYs。

主要发现

  • UDS联合CCA组终身成本比单纯CCA组高1380英镑,QALYs少0.002。
  • 敏感性分析显示结果稳健,但基于FUTURE试验完整病例分析的参数除外。

关键数值与推荐

  • UDS联合CCA相比单纯CCA的增量成本为1380英镑,增量QALYs为-0.002。

临床怎么用

  • 对于难治性OAB女性,常规使用UDS联合CCA可能不具成本效果,需结合亚组谨慎选择。

局限性

  • 模型参数化受当前证据基础限制,尽管使用了FUTURE试验数据。
  • 正在进行的长期随访研究将有助于减少不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the cost-effectiveness of using invasive urodynamic studies (UDS) in the management of women with refractory overactive bladder (OAB) symptoms using the results of the FUTURE trial. PATIENTS AND METHODS: The FUTURE study is the largest randomised controlled trial evaluating the clinical effectiveness of UDS with comprehensive clinical assessment (CCA) in this patient population compared to CCA only. We developed an economic model that replicates the 24-month results of FUTURE, then models the lifetime costs and quality-adjusted life-years (QALYs) using long-term studies of treatment outcomes. RESULTS: Over the patient cohort's lifetime the UDS plus CCA group is £1380 more costly and is associated with 0.002 fewer QALYs than the CCA only group, with only a 23.4% chance of being cost-effective at £20 000 per QALY gained. The sensitivity analysis shows that the results are robust to all changes except for the use of parameters based on the complete case analysis of the FUTURE trial. For the subgroup of patients with an initial diagnosis of mixed urinary incontinence, the UDS group gains more QALYs than the CCA group, albeit at a higher cost. The incremental cost-effectiveness ratio for UDS is £26 462, with a probability of being cost-effective of 45.3% at £20 000 per QALY gained and 53.8% at £30 000 per QALY gained. CONCLUSION: The use of UDS in women with a diagnosis of OAB and whose condition is refractory to initial medical and conservative treatments is unlikely to be cost-effective when examined from a UK perspective and with a lifetime horizon. Despite having access to the FUTURE study data, the parameterisation of the model is limited by the current evidence base. An ongoing long-term follow-up study will help reduce these uncertainties.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bell-Gorrod H, Thokala P, Breeman S, et al. Long-term cost-effectiveness of invasive urodynamic studies for overactive bladder in women. BJU Int. 2025. PMID: 40251913. doi:10.1111/bju.16703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。